Skip to main navigation Skip to search Skip to main content

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist

  • Henry M. Sarau
  • , Don E. Griswold
  • , Brian Bush
  • , William Potts
  • , Punam Sandhu
  • , Dave Lundberg
  • , James J. Foley
  • , Dulcie B. Schmidt
  • , Edward F. Webb
  • , Lenox D. Martin
  • , Jeffrey J. Legos
  • , Robert G. Whitmore
  • , Frank C. Barone
  • , Andrew D. Medhurst
  • , Mark A. Luttmann
  • , Giuseppe A.M. Giardina
  • , Douglas W.P. Hay
  • GlaxoSmithKline
  • SmithKline Beecham Pharmaceuticals

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(α-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide], a human NK-3 receptor (hNK-3R) antagonist, was determined. SB-222200 inhibited 125I-[MePhe7]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a K(i) = 4.4 nM and antagonized NKB-induced Ca2+ mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC50 = 18.4 nM. SB-222200 was selective for hNK-3 receptors compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 250 nM). In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of 125I-[MePhe7]NKB (K(i) = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC50 = 265 nM). In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED50 values of approximately 5 mg/kg. SB-222200 effectively crossed the blood-brain barrier in the mouse and rat. The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concentrations of the compound. Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concentrations (C(max) = about 400 ng/ml) and bioavailability of 46%. The preclinical profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors, in particular in the central nervous system.

Original languageEnglish
Pages (from-to)373-381
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume295
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Dive into the research topics of 'Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist'. Together they form a unique fingerprint.

Cite this